Analysis of the novel factor X gene mutation Glu51Lys in two families with factor X-Riyadh anomaly

Summary

Two families with 'factor X(FX)-Riyadh' have been identified (one of them related to the originally reported family). Affected members of both families exhibit prolongation in prothrombin time (PT) with normal partial thromboplastin time (PTT) and low assay levels of FX, when measured by PT-based assay. They do not have clinical bleeding diathesis, regardless of the PT prolongation. FX genes of the affected family members were analyzed by sequence analysis. A novel missense mutation in exon 4 of the FX gene, which causes the Glu51Lys substitution in the first epidermal growth factor-like domain of FX was found. The Glu51Lys mutation represents a type II mutation with low FX coagulant activity in the extrinsic pathway and normal FX antigen levels. This mutation may result in disruption of the predicted H-bonding between residue Glu51 of FX and the Asn199 residue of the tissue factor (TF) in the FX/TF/factorVIIa ternary complex, producing the phenotype 'FX deficiency Riyadh', with prolonged PT and normal PTT.

Keywords

Prothrombin time - partial thromboplastin time - factor X-Riyadh - exon 4 - mutation

• References

• 1 William WJ, Beutler E, Erslev AJ. et al. Hematology. 2 nd Ed. New York: McGraw Hill; 1977: 1418-1419.
• 2 Al-Hilali AM, Lawson A, Fair DS. Family withfac-torXvariant defective onlyinfactorVIIactivation( X+ Riyadh). AnnSaudiMed 1989; 9: 48-51.
• 3 Lewis SM, Bain B, Bates I. et al. Dacie and Lewis: Practical Haematology. London, Churchill: Livingstone; 2001
• 4 Herrmann FH, Navarette M, Salazar-Sanchez L. et al. Homozygous factor X mutations Gly380Arg and Tyr163delAT are associated with perinatal intracranial hemorrhage. J Pediat 2005; 146: 128-130.
• 5 Denson KW, Lurie A, de Cataldo F. et al. The factor X defect. Recognition of abnormal forms of factor X. Br J Haematol 1970; 18: 317-327.
• 6 Hougie C et al. Stuart clotting defect. J Clin Invest 1957; 36: 485-492.
• 7 Fair DS, Plow EF, Edington TS. Combined functional and immunochemical analysis of normal and abnormal human factor X. J Clin Invest 1979; 64: 884-894.
• 8 Hoffbrand AV, Lewis SM, Tuddenham EG. Postgraduate Haematology. Oxford; Butterworth Heinemann. 1999
• 9 Girolami A, Vicariota M, Ruzza G. et al. Factor X Padua: a “new” congenital factor X abnormality with a defect only in the extrinsic system. Acta Haematol 1985; 73: 31-36.
• 10 Girolami A, Vianello F, Cabrio L. et al. A new mutation (Arg251Trp) in the Ca+ binding site of factor X protease domain appears to be responsible for the defect in the extrinsic pathway activation of factor X Padua. Clin Appl Thromb Hemost 2004; 10: 5-8.
• 11 Herrmann F H, Auserwald G, Ruiz-Saez A. et al. and the Greisfswald Factor X Deficiency Study Group. Factor X deficiency: clinical manifestation of 102 subjects from Europe and Latin America with mutations in the factor X gene. Haemophilia 2006; 12: 479-489.
• 12 Peyvandi F, Menegatti M, Santagostino E. et al. Gene mutations and three-dimensional structural analysis in 13 families with severe factor X deficiency. Br J Haematol 2002; 117: 685-692.
• 13 Venkateswarlu D, Duke RE, Perera L. et al. An allatom solution-equilibrated model for human extrinsic blood coagulation complex (sTF-VII-Xa): A proteinprotein decking and molecular dynamic refinement study. J Thromb Haemost 2003; 1: 2577-2588.